FIELD: biotechnology.
SUBSTANCE: invention relates to an isolated nucleic acid coding a fused protein based on FVIII-BDD (coagulation factor VIII with a deleted B domain) and a heterologous signal peptide, and an expression cassette, a vector and a cell containing same is also provided. Also disclosed is a pharmaceutical composition containing said vector or cassette.
EFFECT: invention is effective for providing FVIII-BDD protein to a subject with hemophilia A, as well as for treating hemophilia A in a subject.
18 cl, 5 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CODON-OPTIMIZED NUCLEIC ACID THAT ENCODES B-DOMAIN-DELETED FACTOR VIII PROTEIN AND ITS USE | 2022 |
|
RU2808564C2 |
| NUCLEIC ACID MOLECULES AND WAYS OF USING THEM | 2018 |
|
RU2819144C2 |
| GENE THERAPY FOR THE TREATMENT OF HEMOPHILIA A | 2017 |
|
RU2762257C2 |
| METHODS OF GENOTHERAPY USING FACTOR VIII (FVIII) GENE | 2018 |
|
RU2808274C2 |
| ANTIBODY WHICH IS CAPABLE OF NEUTRALIZING A SUBSTANCE HAVING AN ACTIVITY OF AN ALTERNATIVE COAGULATION FACTOR FUNCTION VIII (FVIII) | 2015 |
|
RU2737145C2 |
| CPG REDUCED FACTOR VIII VARIANTS, COMPOSITIONS AND METHODS AND USE FOR TREATMENT OF HEMOSTASIS DISORDERS | 2016 |
|
RU2745506C2 |
| GLYCOSYLATED FUSED PROTEINS VWF WITH IMPROVED PHARMACOKINETICS | 2017 |
|
RU2782212C2 |
| USING OF LENTIVIRAL VECTORS EXPRESSING FACTOR VIII | 2019 |
|
RU2803163C2 |
| POLYPEPTIDES MODULATING SIGLEC-DEPENDENT IMMUNE RESPONSES | 2017 |
|
RU2776807C2 |
| TREATMENT METHODS FOR HEMOPHILIA A | 2019 |
|
RU2812863C2 |
